Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study
Sign Up to like & getrecommendations! Published in 2019 at "Brain and Behavior"
DOI: 10.1002/brb3.1332
Abstract: Determination of antibodies against the John Cunningham virus (JCV) is an important tool for risk stratification in Natalizumab‐treated multiple sclerosis (MS) patients. Six‐monthly testing has been suggested for anti‐JCV antibody negative patients and patients with… read more here.
Keywords: john cunningham; antibody; prospective study; cunningham virus ... See more keywords
Amino Acid Uptake, Glucose Metabolism, and Neuroinflammation in John Cunningham Virus Associated Progressive Multifocal Leukoencephalopathy.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000004093
Abstract: ABSTRACT A 69-year-old woman presented with progressive dysarthria and cognitive deficits. On MRI, a T2-hyperintense, non-contrast-enhancing lesion was found in the left precentral area. 18F-FET and 18F-FDG PET scans revealed faint amino acid uptake and… read more here.
Keywords: progressive multifocal; acid uptake; john cunningham; amino acid ... See more keywords
John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "European Neurology"
DOI: 10.1159/000510849
Abstract: Introduction: Presence of anti-JC-virus antibodies (JCVAbs) is associated with the increased risk of natalizumab (NAT)-related progressive multifocal leukoencephalopathy (PML). Little is known about seroconversion rate and time to seroconversion in relapsing-remitting multiple sclerosis (RRMS) patients… read more here.
Keywords: john cunningham; cunningham virus; seroconversion; seroconversion rate ... See more keywords
Changes in John Cunningham virus index in Multiple Sclerosis patients treated with different disease-modifying therapies.
Sign Up to like & getrecommendations! Published in 2021 at "Current neuropharmacology"
DOI: 10.2174/1570159x19666211111123202
Abstract: BACKGROUND Progressive Multifocal Leukoencephalopathy (PML) is an opportunistic infection caused by John Cunningham virus (JCV) reactivation, potentially associated to natalizumab (NTZ) treatment for Multiple Sclerosis (MS). The anti-JCV antibodies titre (JCV index) increases during NTZ… read more here.
Keywords: jcv index; disease modifying; cunningham virus; john cunningham ... See more keywords